Y-mAbs Therapeutics Inc (YMAB)
17.15
-0.10
(-0.58%)
USD |
NASDAQ |
May 03, 16:00
17.11
-0.04
(-0.23%)
After-Hours: 20:00
Y-mAbs Therapeutics Revenue (TTM): 84.82M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 84.82M |
| September 30, 2023 | 92.90M |
| June 30, 2023 | 84.99M |
| March 31, 2023 | 75.03M |
| December 31, 2022 | 65.27M |
| Date | Value |
|---|---|
| September 30, 2022 | 43.42M |
| June 30, 2022 | 39.85M |
| March 31, 2022 | 40.00M |
| December 31, 2021 | 34.90M |
| September 30, 2021 | 46.05M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
34.90M
Minimum
Dec 2021
92.90M
Maximum
Sep 2023
60.72M
Average
55.66M
Median
Revenue (TTM) Benchmarks
| The Cooper Companies Inc | 3.666B |
| Puma Biotechnology Inc | 235.64M |
| Humacyte Inc | -- |
| Moderna Inc | 5.083B |
| NovaBay Pharmaceuticals Inc | 14.73M |